Feasibility Study: Continuous ECG and Blood Pressure Monitoring With the M2VS Sensor System
Feasibility Study for Continuous Monitoring of Electrocardiogram (ECG) and Blood Pressure at the Chest and Upper Arm Using the M2VS System.
In this study, the investigators want to find out whether a new wearable sensor system, called the M2VS system, can reliably measure heart activity, blood pressure, and other vital signs over 24 hours during normal daily life.
The investigators also want to compare the M2VS system with the standard devices currently used for long-term heart and blood pressure monitoring, such as a Holter ECG and an ambulatory blood pressure monitor (ABPM). This will provide an estimation of the accuracy of the M2VS system's ECG and blood pressure measurements compared to the standard devices.
The aim of the study is to assess how reliable the M2VS system is in terms of data completeness and how comfortable it is to wear compared with the usual monitoring devices.
In the future, the results of this study may help make the monitoring of heart and blood vessel diseases more comfortable and easier for patients.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Cardiovascular diseases remain a leading cause of morbidity and mortality worldwide. Long-term ambulatory monitoring of electrocardiography (ECG) and blood pressure is essential for the detection and management of conditions such as paroxysmal atrial fibrillation and masked hypertension. However, current standard monitoring devices, including Holter ECG monitors and ambulatory blood pressure monitors, may be limited by reduced wearing comfort, skin irritation from adhesive electrodes, motion artefacts, and discontinuous blood pressure measurements.
This feasibility study evaluates a novel wearable sensor system, the M2VS system, designed as a flexible textile-based band integrating dry electrodes and multiple sensors for continuous multimodal vital signs monitoring. The system records ECG, photoplethysmography (PPG), inertial measurement unit (IMU) data, body temperature, bioimpedance, acoustic respiratory signals, and piezo sensor data over a 24-hour period in daily life. In this study, the M2VS system will be used strictly as a non-diagnostic data logger.
This study will provide critical insights into the signal quality and technical reliability of a non-invasive, multi-sensor wearable compared to current standard of care (Holter monitor and ABPM). By evaluating the wearable, the research aims to overcome the comfort and compliance barriers of existing monitoring systems. These findings may represent a significant step toward developing more reliable, continuous diagnostic tools for the long-term management of conditions like atrial fibrillation and hypertension.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Jens Eckstein, Prof. Dr.
- Numéro de téléphone: +41 613287689
- E-mail: jens.eckstein@usb.ch
Lieux d'étude
-
-
Canton of Basel-City
-
Basel, Canton of Basel-City, Suisse, 4031
- University Hospital Basel
-
Contact:
- Prof. Dr. med. Jens Eckstein, PhD
- Numéro de téléphone: 0041-61-3287689
- E-mail: jens.eckstein@usb.ch
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Written informed consent obtained prior to any project-specific procedures.
- Age 18 years or older at the time of enrolment.
- Ability to provide valid informed consent.
- Clinical indication for 24-hour Holter monitoring (Holter cohort) or 24-hour ABPM (ABPM cohort).
Exclusion Criteria:
- Insufficient knowledge of the German language, preventing adequate understanding of the project procedures and informed consent.
- Enrolment of the project leader, project staff, their family members, employees, or other dependent persons.
Dermatological and Sensor Placement:
- Pre-existing skin conditions at the application sites (medial upper arm or chest), such as extensive scarring, tattoos, open wounds, active inflammation, or severe oedema that could interfere with sensor coupling or signal quality.
- Excessive hair at the application site that could interfere with sensor coupling or signal quality.
- Presence of other concurrent wearable devices at the same anatomical application site that could interfere with the M2VS system.
- Known allergy to skin-contacting materials utilized in the M2VS system.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Holter cohort
Participants receiving standard of care Holter monitoring will concurrently wear the M2VS system for a 24-hour recording period.
|
The study features a dual-device monitoring approach integrated into the clinical routine: Participants receiving standard of care will concurrently wear the M2VS system for a 24-hour recording period.The M2VS system is designed for multimodal vital sign monitoring.
It comprises a wearable and an associated belt system.
The wearable consists of a battery pack and a recorder unit, that are connected via a sliding mechanism
Questionnaire regarding the usability and wearability of both the M2VS system and the standard of care device.
|
|
ABPM cohort
Participants undergoing standard-of-care ABPM will concurrently wear the M2VS system during the same 24-hour monitoring period.
|
The study features a dual-device monitoring approach integrated into the clinical routine: Participants receiving standard of care will concurrently wear the M2VS system for a 24-hour recording period.The M2VS system is designed for multimodal vital sign monitoring.
It comprises a wearable and an associated belt system.
The wearable consists of a battery pack and a recorder unit, that are connected via a sliding mechanism
Questionnaire regarding the usability and wearability of both the M2VS system and the standard of care device.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Strong signal-to-noise ratio
Délai: 24 hours
|
A strong signal-to-noise ratio (dB), ensuring signals received lie within a range that is physiologically feasible and are usable for further vital sign analysis, and the percentage of continuous, gap-free recording time.
|
24 hours
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Similarity of ECG signal compared to Standard of Care
Délai: 24 hours
|
Agreement of the ECG signal between the investigational M2VS system and the standard of care reference devices.
This evaluates the mean heart rate derived from ECG RR-intervals compared to the 24-hour Holter monitor.
The overall similarity is quantified using the Intraclass Correlation Coefficient.
This is a Unitless index ranging from 0 to 1.
|
24 hours
|
|
Similarity of Systolic Blood Pressure compared to Standard of Care
Délai: 24 hours
|
Agreement of systolic blood pressure between the investigational M2VS system and the standard of care reference devices.
This evaluates the estimated systolic blood pressure derived from Pulse Arrival Time (using synchronous M2VS ECG and PPG signals) compared to the 24-hour Ambulatory Blood Pressure Monitor (ABPM).
The overall similarity for these metrics is quantified using the Intraclass Correlation Coefficient.
This is a Unitless index ranging from 0 to 1.
|
24 hours
|
|
Similarity of Diastolic Blood Pressure compared to Standard of Care
Délai: 24 hours
|
Agreement of diastolic blood pressure between the investigational M2VS system and the standard of care reference devices.
This evaluates the estimated diastolic blood pressure derived from Pulse Arrival Time (using synchronous M2VS ECG and PPG signals) compared to the 24-hour Ambulatory Blood Pressure Monitor (ABPM).
The overall similarity for these metrics is quantified using the Intraclass Correlation Coefficient.
This is a Unitless index ranging from 0 to 1.
|
24 hours
|
|
Reliability compared to Standard of Care
Délai: 24 hours
|
Quantification of the signal reliability and technical performance of the investigational M2VS system compared to the standard of care reference devices.
This evaluates the technical data continuity and signal quality, measured as the percentage of the total recording period where the ECG and PPG data packets are continuous, gap-free, and meet acceptable Signal-to-Noise Ratio (SNR) and physiological thresholds to be considered usable.
|
24 hours
|
|
Wearability of M2VS
Délai: After the 24-hour monitoring period
|
Participant-reported wearability of the M2VS system compared to standard of care devices, assessed via a structured questionnaire administered upon device removal.
Responses are measured on a Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree).
Scores from reverse-coded items will be inverted before the mean score is calculated.
A higher mean score indicates better usability and wearability.
|
After the 24-hour monitoring period
|
|
Localization of Physical Discomfort
Délai: 24 hours (Upon device removal)
|
Participant-reported areas of discomfort marked on a body map and supplemented by qualitative notes on the corresponding area.
|
24 hours (Upon device removal)
|
|
Acceptance compared to Standard of Care
Délai: 24 hours (Upon device removal)
|
Participant acceptance of the M2VS device compared to standard of care devices, assessed via the Net Promoter Score (NPS).
The NPS is calculated using a single question ("How likely are you to recommend...?") on a scale from 0 (not at all likely) to 10 (extremely likely).
The final NPS ranges from 0 to 10, where a higher score indicates a higher level of participant acceptance.
|
24 hours (Upon device removal)
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Jens Eckstein, Prof. Dr., University Hospital, Basel, Switzerland
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2026-01087; am25eckstein2
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .